Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer

This study aims to confirm the safety and efficacy of fruquintinib combined with standard chemotherapy, further compare whether first-line standard chemotherapy has superiority, bring better survival benefits to patients with pMMR endometrial cancer, and provide more options for patients with late recurrent and metastatic endometrial cancer.